AP NEWS

Genevant President & CEO Dr. Bo Rode Hansen to Present at Biotech Showcase 2019

January 3, 2019

BOSTON & BURNABY, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Jan 3, 2019--Genevant Sciences, a leading biopharmaceutical company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics across multiple modalities, announced today that its President & CEO Dr. Bo Rode Hansen will present a corporate update on Monday, January 7, 2019, at 2:15 PM PT at the Biotech Showcase 2019. The presentation will be in Franciscan D on the Ballroom level of the Hilton San Francisco Union Square.

About Genevant Sciences At Genevant, we aim to deliver innovative and meaningful therapies that improve the lives of people through our diverse pipeline of nucleic acid-based medicines. By pursuing a multiple modality “pan-RNA” approach to drug discovery and development, we are well-positioned to select and advance the best therapeutic approach for each disease area. Our rapidly growing pipeline is founded on our proprietary ligand conjugate platform and best-in-class lipid nanoparticle (LNP) delivery technology, which enabled the first RNAi product approval. Through our own internal development programs and strategic partnerships, we are committed to transforming the future of human health.

To learn more about us, please visit: www.genevant.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005076/en/

CONTACT: Media:

Karen Sharma

MacDougall Biomedical Communications

ksharma@macbiocom.com

Investor:

investors@genevant.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA CANADA CALIFORNIA MASSACHUSETTS SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: Genevant Sciences

Copyright Business Wire 2019.

PUB: 01/03/2019 08:00 AM/DISC: 01/03/2019 08:01 AM

http://www.businesswire.com/news/home/20190103005076/en

AP RADIO
Update hourly